Trials / Conditions / Unresectable Leiomyosarcoma

Unresectable Leiomyosarcoma

9 registered clinical trials studyying Unresectable Leiomyosarcoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma NCT06571734	Northwestern University	Phase 2
Recruiting	Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposert NCT05711615	National Cancer Institute (NCI)	Phase 1
Withdrawn	Niraparib for the Treatment of Leiomyosarcoma NCT05174455	David Liebner, MD	Phase 2
Active Not Recruiting	Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advan NCT05836571	National Cancer Institute LAO	Phase 2
Active Not Recruiting	Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tis NCT04200443	City of Hope Medical Center	Phase 2
Terminated	Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot NCT03074318	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot B NCT03009201	OHSU Knight Cancer Institute	Phase 1
Terminated	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma NCT02601209	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma NCT02428192	National Cancer Institute (NCI)	Phase 2